Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection.


Journal

The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030

Informations de publication

Date de publication:
05 2020
Historique:
entrez: 2 5 2020
pubmed: 2 5 2020
medline: 2 7 2020
Statut: ppublish

Résumé

Helicobacter pylori (HP) infection is associated with many gastrointestinal disorders, including gastric cancer, and consensus guidelines recommend eradication after detection. There is a theoretical, yet uninvestigated, concern that HP treatment could increase the risk of Clostridium difficile infection (CDI). Using the data from a large cohort of patients with HP, we investigated whether HP eradication is associated with CDI. A retrospective cohort study within the Veterans Health Administration on 38,535 patients (median age 61.8 years; 91.8% men) with detected HP between January 1, 1994, and December 31, 2018 was conducted. Primary outcome was a positive laboratory test for CDI within 3 months of HP detection. Multivariable logistic regression evaluated the following: patient demographics, previous CDI, recent hospitalization, and whether the patient received HP eradication therapy (by antibiotic and regimen, and including proton pump therapy). Secondary analysis of those treated evaluated whether eradication of HP was associated with CDI. Among 38,535 patients, 28,818 (74.8%) were treated for HP and 284 (0.74%) developed CDI. In multivariable analysis, prominent factors included hospital discharge within 12 weeks (odds ratio [OR] 2.15; 95% confidence interval [CI]: 1.22-3.77) and 4 weeks (OR 3.46; 95% CI: 2.18-5.48), P < 0.001, and previous CDI (OR 12.5; 95% CI: 9.21-17.0, P < 0.001). Treatment of HP was not associated with future CDI. In secondary analysis of those treated, confirmation of eradication was not associated with future CDI (OR 1.49; 95% CI: 0.67-3.29). In a large study of US patients with HP, we demonstrate that neither treatment nor eradication of HP is associated with CDI. Previous C. difficile infection and recent hospital discharge, established risk factors for CDI, are strongly associated. These findings suggest that treatment should be continued to be prescribed when HP is detected (http://links.lww.com/AJG/B507).

Identifiants

pubmed: 32356953
doi: 10.14309/ajg.0000000000000626
pii: 00000434-202005000-00019
pmc: PMC7202442
mid: NIHMS1578696
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

716-722

Subventions

Organisme : NIDDK NIH HHS
ID : T32 DK007740
Pays : United States

Références

J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52
pubmed: 17047193
Gastroenterology. 2020 Feb;158(3):527-536.e7
pubmed: 31654635
BMC Infect Dis. 2016 Nov 8;16(1):656
pubmed: 27825317
Am J Gastroenterol. 2017 Feb;112(2):212-239
pubmed: 28071659
J Antimicrob Chemother. 2012 Jul;67 Suppl 1:i51-63
pubmed: 22855879
N Engl J Med. 2019 Mar 21;380(12):1158-1165
pubmed: 30893536
Lancet Infect Dis. 2006 Nov;6(11):699-709
pubmed: 17067919
Infect Control Hosp Epidemiol. 2001 Sep;22(9):572-5
pubmed: 11732787
Gastroenterology. 2019 Jul;157(1):44-53
pubmed: 30998990
J Clin Microbiol. 2019 Oct 23;57(11):
pubmed: 31434726
J Antimicrob Chemother. 2016 Jul;71(7):1800-6
pubmed: 27040304
Am J Gastroenterol. 1998 Jul;93(7):1175-6
pubmed: 9672359
EMBO Rep. 2006 May;7(5):470-3
pubmed: 16670677
Clin Gastroenterol Hepatol. 2018 Jul;16(7):992-1002.e6
pubmed: 29559361
Cancer Prev Res (Phila). 2008 Oct;1(5):329-38
pubmed: 19138977
Infect Control Hosp Epidemiol. 2012 Jan;33(1):20-8
pubmed: 22173518
J Intern Med. 1998 Mar;243(3):251-3
pubmed: 9627163
J Antimicrob Chemother. 2012 Mar;67(3):742-8
pubmed: 22146873
Cleve Clin J Med. 2018 Dec;85(12):928-930
pubmed: 30526758
World J Gastroenterol. 2013 Nov 14;19(42):7476-9
pubmed: 24259981
Emerg Infect Dis. 2006 Mar;12(3):409-15
pubmed: 16704777
Middle East J Dig Dis. 2016 Jul;8(3):219-225
pubmed: 27698972
Gut. 2017 Jan;66(1):6-30
pubmed: 27707777
FASEB J. 2014 Sep;28(9):3821-3822
pubmed: 29405744
J Pediatr. 2013 Sep;163(3):627-30
pubmed: 23759424
World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):392-9
pubmed: 25400982
J Natl Cancer Inst. 2006 Oct 18;98(20):1432-4
pubmed: 17047185
Microbiol Immunol. 2008 Mar;52(3):156-61
pubmed: 18402597
Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S12-8
pubmed: 18177217
MMWR Morb Mortal Wkly Rep. 2008 Apr 4;57(13):340-3
pubmed: 18385641
Scand J Gastroenterol. 1999 Apr;34(4):353-60
pubmed: 10365894
N Engl J Med. 2015 Feb 26;372(9):825-34
pubmed: 25714160
J Am Med Inform Assoc. 2013 Jul-Aug;20(4):652-8
pubmed: 23396545

Auteurs

Shria Kumar (S)

Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

David C Metz (DC)

Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

David E Kaplan (DE)

Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Gastroenterology, Veterans Health Administration, Philadelphia, Pennsylvania, USA.

David S Goldberg (DS)

Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH